FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2002;346(16):1258.

Previous Volume 345:319-324 August 2, 2001 Number 5 Next

	Full Text PDF Editorial by Loscalzo, J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article PubMed Citation

ABSTRACT

Background Most patients with primary pulmonary hypertension are thought to have sporadic, not inherited, disease. Because clinical disease develops in only 10 to 20 percent of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that many patients with apparently sporadic primary pulmonary hypertension may actually have familial primary pulmonary hypertension.

Methods In a study conducted over 20 years, we developed a registry of 67 families affected by familial primary pulmonary hypertension. Through patient referrals, extensive family histories, and correlation of family pedigrees, we discovered shared ancestry among five subfamilies. We assessed some family members for mutations in the gene encoding bone morphogenetic protein receptor II (BMPR2), which has recently been found to cause familial primary pulmonary hypertension.

Results We linked five separately identified subfamilies that included 394 known members spanning seven generations, which were traced back to a founding couple in the mid-1800s. Familial primary pulmonary hypertension has been diagnosed in 18 family members, 12 of whom were first thought to have sporadic disease. The conditions of 7 of the 18 were initially misdiagnosed as other cardiopulmonary diseases. Six members affected with familial primary pulmonary hypertension and 6 of 10 at risk for carriage have undergone genotype analysis, and they have the same mutation in BMPR2, a transversion of thymine to guanine at position 354 in exon 3.

Conclusions Many cases of apparently sporadic primary pulmonary hypertension may be familial. The recent discovery of mutations in BMPR2 should make it possible to identify those with susceptibility to the disease.

Source Information

From the Center for Lung Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine (J.H.N., L.W., K.B.L., E.L., R.G., J.E.L.), and the Division of Medical Genetics, Department of Pediatrics (J.A.P.), Vanderbilt University School of Medicine, Nashville.

Address reprint requests to Dr. Newman at the Allergy, Pulmonary, and Critical Care Division, T-1218, Vanderbilt University Medical Center North, Nashville, TN 37232-2650, or at john.newman{at}med.va.gov.

Full Text of this Article

This article has been cited by other articles:

• Song, Y., Coleman, L., Shi, J., Beppu, H., Sato, K., Walsh, K., Loscalzo, J., Zhang, Y.-Y. (2008). Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am. J. Physiol. Heart Circ. Physiol. 295: H677-H690 [Abstract] [Full Text]  
• Sztrymf, B., Coulet, F., Girerd, B., Yaici, A., Jais, X., Sitbon, O., Montani, D., Souza, R., Simonneau, G., Soubrier, F., Humbert, M. (2008). Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. Am. J. Respir. Crit. Care Med. 177: 1377-1383 [Abstract] [Full Text]  
• Newman, J. H., Phillips, J. A. III, Loyd, J. E. (2008). Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies. ANN INTERN MED 148: 278-283 [Abstract] [Full Text]  
• Suntharalingam, J., Machado, R. D, Sharples, L. D, Toshner, M. R, Sheares, K. K, Hughes, R. J, Jenkins, D. P, Trembath, R. C, Morrell, N. W, Pepke-Zaba, J. (2007). Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax 62: 617-622 [Abstract] [Full Text]  
• Tidswell, M., Higgins, T. L. (2007). The Anesthesiologist and Pulmonary Arterial Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 93-95  
• Klinger, J. R. (2007). Pulmonary Arterial Hypertension: An Overview. SEMIN CARDIOTHORAC VASC ANESTH 11: 96-103 [Abstract]  
• Edelman, J. D. (2007). Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 110-118 [Abstract]  
• Said, S. I., Hamidi, S. A., Dickman, K. G., Szema, A. M., Lyubsky, S., Lin, R. Z., Jiang, Y.-P., Chen, J. J., Waschek, J. A., Kort, S. (2007). Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene. Circulation 115: 1260-1268 [Abstract] [Full Text]  
• Johnson, R. C., Leopold, J. A., Loscalzo, J. (2006). Vascular Calcification: Pathobiological Mechanisms and Clinical Implications. Circ. Res. 99: 1044-1059 [Abstract] [Full Text]  
• Morrell, N. W. (2006). Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling?. Proc Am Thorac Soc 3: 680-686 [Abstract] [Full Text]  
• Fantozzi, I., Platoshyn, O., Wong, A. H., Zhang, S., Remillard, C. V., Furtado, M. R., Petrauskene, O. V., Yuan, J. X.-J. (2006). Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L993-L1004 [Abstract] [Full Text]  
• Said, S. I. (2006). Mediators and modulators of pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L547-L558 [Abstract] [Full Text]  
• Miriyala, S., Gongora Nieto, M. C., Mingone, C., Smith, D., Dikalov, S., Harrison, D. G., Jo, H. (2006). Bone Morphogenic Protein-4 Induces Hypertension in Mice: Role of Noggin, Vascular NADPH Oxidases, and Impaired Vasorelaxation. Circulation 113: 2818-2825 [Abstract] [Full Text]  
• Varghese, A., Hong, Z., Weir, E. K. (2006). Serotonin-Induced Inhibition of KV Current: A Supporting Role in Pulmonary Vasoconstriction?. Circ. Res. 98: 860-862 [Full Text]  
• Takahashi, H., Goto, N., Kojima, Y., Tsuda, Y., Morio, Y., Muramatsu, M., Fukuchi, Y. (2006). Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L450-L458 [Abstract] [Full Text]  
• Rubin, L. J. (2006). Pulmonary arterial hypertension.. Proc Am Thorac Soc 3: 111-115 [Abstract] [Full Text]  
• Nicolls, M. R., Taraseviciene-Stewart, L., Rai, P. R., Badesch, D. B., Voelkel, N. F. (2005). Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 26: 1110-1118 [Abstract] [Full Text]  
• Sandifer, B. L., Brigham, K. L., Lawrence, E. C., Mottola, D., Cuppels, C., Parker, R. E. (2005). Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J. Appl. Physiol. 99: 2363-2368 [Abstract] [Full Text]  
• Sweet, K., Willis, J., Zhou, X.-P., Gallione, C., Sawada, T., Alhopuro, P., Khoo, S. K., Patocs, A., Martin, C., Bridgeman, S., Heinz, J., Pilarski, R., Lehtonen, R., Prior, T. W., Frebourg, T., Teh, B. T., Marchuk, D. A., Aaltonen, L. A., Eng, C. (2005). Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA 294: 2465-2473 [Abstract] [Full Text]  
• Hong, Z., Smith, A. J., Archer, S. L., Wu, X.-C., Nelson, D. P., Peterson, D., Johnson, G., Weir, E. K. (2005). Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction. Circulation 112: 1494-1499 [Abstract] [Full Text]  
• Stewart, D. J. (2005). Bone Morphogenetic Protein Receptor-2 and Pulmonary Arterial Hypertension: Unraveling a Riddle Inside an Enigma?. Circ. Res. 96: 1033-1035 [Full Text]  
• Yang, X., Long, L., Southwood, M., Rudarakanchana, N., Upton, P. D., Jeffery, T. K., Atkinson, C., Chen, H., Trembath, R. C., Morrell, N. W. (2005). Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension. Circ. Res. 96: 1053-1063 [Abstract] [Full Text]  
• Herrick, A. L. (2005). Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44: 587-596 [Abstract] [Full Text]  
• Rashid, A, Ivy, D (2005). Severe paediatric pulmonary hypertension: new management strategies. Arch. Dis. Child. 90: 92-98 [Abstract] [Full Text]  
• Beppu, H., Ichinose, F., Kawai, N., Jones, R. C., Yu, P. B., Zapol, W. M., Miyazono, K., Li, E., Bloch, K. D. (2004). BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 287: L1241-L1247 [Abstract] [Full Text]  
• Farber, H. W., Loscalzo, J. (2004). Pulmonary Arterial Hypertension. NEJM 351: 1655-1665 [Full Text]  
• Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R. C., Shah, P. K., Rajavashisth, T. B. (2004). Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification. Endocr. Rev. 25: 629-672 [Abstract] [Full Text]  
• Newman, J. H., Fanburg, B. L., Archer, S. L., Badesch, D. B., Barst, R. J., Garcia, J. G.N., Kao, P. N., Knowles, J. A., Loyd, J. E., McGoon, M. D., Morse, J. H., Nichols, W. C., Rabinovitch, M., Rodman, D. M., Stevens, T., Tuder, R. M., Voelkel, N. F., Gail, D. B. (2004). Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop. Circulation 109: 2947-2952 [Full Text]  
• Simonneau, G., Galie, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., Rich, S., Fishman, A. (2004). Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S-12S [Abstract] [Full Text]  
• Newman, J. H., Trembath, R. C., Morse, J. A., Grunig, E., Loyd, J. E., Adnot, S., Coccolo, F., Ventura, C., Phillips, J. A. III, Knowles, J. A., Janssen, B., Eickelberg, O., Eddahibi, S., Herve, P., Nichols, W. C., Elliott, G. (2004). Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 43: 33S-39S [Abstract] [Full Text]  
• Rabinovitch, M. (2004). The Mouse Through the Looking Glass: A New Door Into the Pathophysiology of Pulmonary Hypertension. Circ. Res. 94: 1001-1004 [Full Text]  
• Napoli, C., Loscalzo, J. (2004). Nitric Oxide and Other Novel Therapies for Pulmonary Hypertension. J CARDIOVASC PHARMACOL THER 9: 1-8 [Abstract]  
• Remillard, C. V., Yuan, J. X.-J. (2004). Activation of K+ channels: an essential pathway in programmed cell death. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L49-L67 [Abstract] [Full Text]  
• Zhang, S., Fantozzi, I., Tigno, D. D., Yi, E. S., Platoshyn, O., Thistlethwaite, P. A., Kriett, J. M., Yung, G., Rubin, L. J., Yuan, J. X.-J. (2003). Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L740-L754 [Abstract] [Full Text]  
• Abdalla, S A, Geisthoff, U W, Bonneau, D, Plauchu, H, McDonald, J, Kennedy, S, Faughnan, M E, Letarte, M (2003). Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J. Med. Genet. 40: 494-502 [Abstract] [Full Text]  
• Kao, P. N., Faul, J. L. (2003). Emerging therapies for pulmonary hypertension: Striving for efficacy and safety. J Am Coll Cardiol 41: 2126-2129 [Full Text]  
• Hu, M. C., Piscione, T. D., Rosenblum, N. D. (2003). Elevated SMAD1/{beta}-catenin molecular complexes and renal medullary cystic dysplasia in ALK3 transgenic mice. Development 130: 2753-2766 [Abstract] [Full Text]  
• Peacock, A. J (2003). Treatment of pulmonary hypertension. BMJ 326: 835-836 [Full Text]  
• Runo, J. R., Vnencak-Jones, C. L., Prince, M., Loyd, J. E., Wheeler, L., Robbins, I. M., Lane, K. B., Newman, J. H., Johnson, J., Nichols, W. C., Phillips, J. A. III (2003). Pulmonary Veno-occlusive Disease Caused by an Inherited Mutation in Bone Morphogenetic Protein Receptor II. Am. J. Respir. Crit. Care Med. 167: 889-894 [Abstract] [Full Text]  
• Du, L., Sullivan, C. C., Chu, D., Cho, A. J., Kido, M., Wolf, P. L., Yuan, J. X.-J., Deutsch, R., Jamieson, S. W., Thistlethwaite, P. A. (2003). Signaling Molecules in Nonfamilial Pulmonary Hypertension. NEJM 348: 500-509 [Abstract] [Full Text]  
• Eddahibi, S., Morrell, N., d'Ortho, M-P., Naeije, R., Adnot, S. (2002). Pathobiology of pulmonary arterial hypertension. Eur Respir J 20: 1559-1572 [Abstract] [Full Text]  
• Loyd, J. E. (2002). Genetics and Pulmonary Hypertension. Chest 122: 284S-286S [Abstract] [Full Text]  
• Nishimura, T., Faul, J. L., Berry, G. J., Vaszar, L. T., Qiu, D., Pearl, R. G., Kao, P. N. (2002). Simvastatin Attenuates Smooth Muscle Neointimal Proliferation and Pulmonary Hypertension in Rats. Am. J. Respir. Crit. Care Med. 166: 1403-1408 [Abstract] [Full Text]  
• Mitani, Y., Mutlu, A., Russell, J. C., Brindley, D. N., DeAlmeida, J., Rabinovitch, M. (2002). Dexfenfluramine protects against pulmonary hypertension in rats. J. Appl. Physiol. 93: 1770-1778 [Abstract] [Full Text]  
• Chatterjee, K., De Marco, T., Alpert, J. S. (2002). Pulmonary Hypertension: Hemodynamic Diagnosis and Management. Arch Intern Med 162: 1925-1933 [Abstract] [Full Text]  
• Dinh-Xuan, A.T., Humbert, M., Naeije, R. (2002). Severe pulmonary hypertension: walking through new paths to revisit an old field. Eur Respir J 20: 509-510 [Full Text]  
• Humbert, M., Trembath, R.C. (2002). Genetics of pulmonary hypertension: from bench to bedside. Eur Respir J 20: 741-749 [Abstract] [Full Text]  
• Marian, A.J., Boerwinkle, E. (2002). "Into Thin Air" and the Genetics of Complex Traits. Circulation 106: 768-769 [Full Text]  
• Harris, S.E., Chand, A.L., Winship, I.M., Gersak, K., Aittomaki, K., Shelling, A.N. (2002). Identification of novel mutations in FOXL2 associated with premature ovarian failure. Mol Hum Reprod 8: 729-733 [Abstract] [Full Text]  
• Hoeper, M. M., Galie, N., Simonneau, G., Rubin, L. J. (2002). New Treatments for Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 165: 1209-1216 [Full Text]  
• Newman, J. H. (2002). Treatment of Primary Pulmonary Hypertension -- The Next Generation. NEJM 346: 933-935 [Full Text]  
• Kim, N. H.S., Rubin, L. J. (2002). Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension. J CARDIOVASC PHARMACOL THER 7: 9-19 [Abstract]  
• Loyd, J. E. (2002). Genetics and Gene Expression in Pulmonary Hypertension : Parker B. Francis Lecture. Chest 121: 46S-50S [Abstract] [Full Text]  
• Loscalzo, J. (2001). Genetic Clues to the Cause of Primary Pulmonary Hypertension. NEJM 345: 367-371 [Full Text]